Skip to main content
Erschienen in: Virchows Archiv 4/2016

11.07.2016 | Original Article

Whole-transcriptome analysis of chordoma of the skull base

verfasst von: Diana Bell, Shaan M. Raza, Achim H. Bell, Gregory N. Fuller, Franco DeMonte

Erschienen in: Virchows Archiv | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Fourteen skull base chordoma specimens and three normal specimens were microdissected from paraffin-embedded tissue. Pools of RNA from highly enriched preparations of these cell types were subjected to expression profiling using whole-transcriptome shotgun sequencing. Using strict criteria, 294 differentially expressed transcripts were found, with 28 % upregulated and 72 % downregulated. The transcripts were annotated using NCBI Entrez Gene and computationally analyzed with the Ingenuity Pathway Analysis program. From these significantly changed expressions, the analysis identified 222 cancer-related transcripts. These 294 differentially expressed genes and non-coding RNA transcripts provide here a set to specifically define skull base chordomas and to identify novel and potentially important targets for diagnosis, prognosis, and therapy of this cancer. Significance Genomic profiling to subtype skull base chordoma reveals potential candidates for specific biomarkers, with validation by IHC for selected candidates. The highly expressed developmental genes T, LMX1A, ZIC4, LHX4, and HOXA1 may be potential drivers of this disease.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Lee J, Bhatia NN, Hoang BH, Ziogas A, Zell JA (2012) Analysis of prognostic factors for patients with chordoma with use of the California Cancer Registry. J Bone Joint Surg Am 94:356–363PubMed Lee J, Bhatia NN, Hoang BH, Ziogas A, Zell JA (2012) Analysis of prognostic factors for patients with chordoma with use of the California Cancer Registry. J Bone Joint Surg Am 94:356–363PubMed
3.
Zurück zum Zitat Mitchell A, Scheithauer BW, Unni KK, Forsyth PJ, Wold LE, McGivney DJ (1993) Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer 72:2943–2949CrossRefPubMed Mitchell A, Scheithauer BW, Unni KK, Forsyth PJ, Wold LE, McGivney DJ (1993) Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer 72:2943–2949CrossRefPubMed
4.
Zurück zum Zitat Noel G, Habrand JL, Jauffret E, de Crevoisier R, Dederke S, Mammar H, et al. (2003) Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol 179:241–248CrossRefPubMed Noel G, Habrand JL, Jauffret E, de Crevoisier R, Dederke S, Mammar H, et al. (2003) Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol 179:241–248CrossRefPubMed
5.
Zurück zum Zitat Ruosi C, Colella G, Di Donato SL, Granata F, Di Salvatore MG, Fazioli F (2015) Surgical treatment of sacral chordoma: survival and prognostic factors. Eur Spine J 24(Suppl 7):912–917CrossRefPubMed Ruosi C, Colella G, Di Donato SL, Granata F, Di Salvatore MG, Fazioli F (2015) Surgical treatment of sacral chordoma: survival and prognostic factors. Eur Spine J 24(Suppl 7):912–917CrossRefPubMed
6.
Zurück zum Zitat Thieblemont C, Biron P, Rocher F, Bouhour D, Bobin JY, Gerard JP, et al. (1995) Prognostic factors in chordoma: role of postoperative radiotherapy. Eur J Cancer 31A:2255–2259CrossRefPubMed Thieblemont C, Biron P, Rocher F, Bouhour D, Bobin JY, Gerard JP, et al. (1995) Prognostic factors in chordoma: role of postoperative radiotherapy. Eur J Cancer 31A:2255–2259CrossRefPubMed
7.
Zurück zum Zitat Varga PP, Szoverfi Z, Fisher CG, Boriani S, Gokaslan ZL, Dekutoski MB, et al. (2015) Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival. Eur Spine J 24:1092–1101CrossRefPubMed Varga PP, Szoverfi Z, Fisher CG, Boriani S, Gokaslan ZL, Dekutoski MB, et al. (2015) Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival. Eur Spine J 24:1092–1101CrossRefPubMed
8.
Zurück zum Zitat von Witzleben A, Goerttler LT, Marienfeld R, Barth H, Lechel A, Mellert K, et al. (2015) Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4/6 cell-cycle pathway. Cancer Res 75:3823–3831CrossRef von Witzleben A, Goerttler LT, Marienfeld R, Barth H, Lechel A, Mellert K, et al. (2015) Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4/6 cell-cycle pathway. Cancer Res 75:3823–3831CrossRef
9.
Zurück zum Zitat Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, et al. (2016) EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J Pathol 239(3):320–334CrossRefPubMedPubMedCentral Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, et al. (2016) EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J Pathol 239(3):320–334CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Wolf JB (2013) Principles of transcriptome analysis and gene expression quantification: an RNA-Seq tutorial. Mol Ecol Resour 13:559–572CrossRefPubMed Wolf JB (2013) Principles of transcriptome analysis and gene expression quantification: an RNA-Seq tutorial. Mol Ecol Resour 13:559–572CrossRefPubMed
13.
Zurück zum Zitat Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. (2013) STAR: ultrafast universal RNA-Seq aligner. Bioinformatics 29:15–21CrossRefPubMed Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. (2013) STAR: ultrafast universal RNA-Seq aligner. Bioinformatics 29:15–21CrossRefPubMed
14.
Zurück zum Zitat Barresi V, Ieni A, Branca G, Tuccari G (2014) Brachyury: a diagnostic marker for the differential diagnosis of chordoma and hemangioblastoma versus neoplastic histological mimickers. Dis Markers 2014:514753CrossRefPubMedPubMedCentral Barresi V, Ieni A, Branca G, Tuccari G (2014) Brachyury: a diagnostic marker for the differential diagnosis of chordoma and hemangioblastoma versus neoplastic histological mimickers. Dis Markers 2014:514753CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Faial T, Bernardo AS, Mendjan S, Diamanti E, Ortmann D, Gentsch GE, et al. (2015) Brachyury and SMAD signalling collaboratively orchestrate distinct mesoderm and endoderm gene regulatory networks in differentiating human embryonic stem cells. Development 142:2121–2135 Faial T, Bernardo AS, Mendjan S, Diamanti E, Ortmann D, Gentsch GE, et al. (2015) Brachyury and SMAD signalling collaboratively orchestrate distinct mesoderm and endoderm gene regulatory networks in differentiating human embryonic stem cells. Development 142:2121–2135
16.
Zurück zum Zitat Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, et al. (2008) Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol 32:572–580 Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, et al. (2008) Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol 32:572–580
17.
Zurück zum Zitat Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, et al. (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209:157–165 Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, et al. (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209:157–165
18.
Zurück zum Zitat Pinto F, Pertega-Gomes N, Pereira MS, Vizcaino JR, Monteiro P, Henrique RM, et al. (2014) T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clin Cancer Res 20:4949–4961CrossRefPubMed Pinto F, Pertega-Gomes N, Pereira MS, Vizcaino JR, Monteiro P, Henrique RM, et al. (2014) T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clin Cancer Res 20:4949–4961CrossRefPubMed
19.
Zurück zum Zitat Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, et al. (2009) T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 41:1176–1178CrossRefPubMedPubMedCentral Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, et al. (2009) T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 41:1176–1178CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, et al. (2014) Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. J Natl Cancer Inst 106 Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, et al. (2014) Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. J Natl Cancer Inst 106
21.
Zurück zum Zitat Fathi A, Rasouli H, Yeganeh M, Salekdeh GH, Baharvand H (2015) Efficient differentiation of human embryonic stem cells toward dopaminergic neurons using recombinant LMX1A factor. Mol Biotechnol 57:184–194CrossRefPubMed Fathi A, Rasouli H, Yeganeh M, Salekdeh GH, Baharvand H (2015) Efficient differentiation of human embryonic stem cells toward dopaminergic neurons using recombinant LMX1A factor. Mol Biotechnol 57:184–194CrossRefPubMed
22.
Zurück zum Zitat Cai J, Donaldson A, Yang M, German MS, Enikolopov G, Iacovitti L (2009) The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson’s disease model. Stem Cells 27:220–229CrossRefPubMed Cai J, Donaldson A, Yang M, German MS, Enikolopov G, Iacovitti L (2009) The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson’s disease model. Stem Cells 27:220–229CrossRefPubMed
23.
Zurück zum Zitat Dong W, Feng L, Xie Y, Zhang H, Wu Y (2011) Hypermethylation-mediated reduction of LMX1A expression in gastric cancer. Cancer Sci 102:361–366CrossRefPubMed Dong W, Feng L, Xie Y, Zhang H, Wu Y (2011) Hypermethylation-mediated reduction of LMX1A expression in gastric cancer. Cancer Sci 102:361–366CrossRefPubMed
24.
Zurück zum Zitat Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J (2004) Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 62:778–782CrossRefPubMedPubMedCentral Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J (2004) Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 62:778–782CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Filges I, Bischof-Renner A, Rothlisberger B, Potthoff C, Glanzmann R, Gunthard J, et al. (2012) Panhypopituitarism presenting as life-threatening heart failure caused by an inherited microdeletion in 1q25 including LHX4. Pediatrics 129:e529–e534CrossRefPubMed Filges I, Bischof-Renner A, Rothlisberger B, Potthoff C, Glanzmann R, Gunthard J, et al. (2012) Panhypopituitarism presenting as life-threatening heart failure caused by an inherited microdeletion in 1q25 including LHX4. Pediatrics 129:e529–e534CrossRefPubMed
26.
Zurück zum Zitat Cha N, Liu W, Yang N, Xie S, Gao Y, Chen X, et al. (2014) Oncogenicity of LHX4 in colorectal cancer through Wnt/beta-catenin/TCF4 cascade. Tumour Biol 35:10319–10324CrossRefPubMed Cha N, Liu W, Yang N, Xie S, Gao Y, Chen X, et al. (2014) Oncogenicity of LHX4 in colorectal cancer through Wnt/beta-catenin/TCF4 cascade. Tumour Biol 35:10319–10324CrossRefPubMed
27.
Zurück zum Zitat Bitu CC, Destro MF, Carrera M, da Silva SD, Graner E, Kowalski LP, et al. (2012) HOXA1 is overexpressed in oral squamous cell carcinomas and its expression is correlated with poor prognosis. BMC Cancer 12:146CrossRefPubMedPubMedCentral Bitu CC, Destro MF, Carrera M, da Silva SD, Graner E, Kowalski LP, et al. (2012) HOXA1 is overexpressed in oral squamous cell carcinomas and its expression is correlated with poor prognosis. BMC Cancer 12:146CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Zha TZ, BS H, HF Y, Tan YF, Zhang Y, Zhang K (2012) Overexpression of HOXA1 correlates with poor prognosis in patients with hepatocellular carcinoma. Tumour Biol 33:2125–2134CrossRefPubMed Zha TZ, BS H, HF Y, Tan YF, Zhang Y, Zhang K (2012) Overexpression of HOXA1 correlates with poor prognosis in patients with hepatocellular carcinoma. Tumour Biol 33:2125–2134CrossRefPubMed
29.
Zurück zum Zitat Wardwell-Ozgo J, Dogruluk T, Gifford A, Zhang Y, Heffernan TP, van Doorn R, et al. (2014) HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 33:1017–1026CrossRefPubMed Wardwell-Ozgo J, Dogruluk T, Gifford A, Zhang Y, Heffernan TP, van Doorn R, et al. (2014) HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 33:1017–1026CrossRefPubMed
Metadaten
Titel
Whole-transcriptome analysis of chordoma of the skull base
verfasst von
Diana Bell
Shaan M. Raza
Achim H. Bell
Gregory N. Fuller
Franco DeMonte
Publikationsdatum
11.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 4/2016
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-016-1985-y

Weitere Artikel der Ausgabe 4/2016

Virchows Archiv 4/2016 Zur Ausgabe

Editorial

In this issue

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …